知镜 Cognispect · 医学文献与研究工作台

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having 'bifunctional' bronchodilator and anti-inflammatory activity.

Page C.
British journal of pharmacology · 2026-07-05 · PMID 42402420

文献摘要

Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti-inflammatory activity via PDE4 inhibition. Following extensive preclinical and clinical investigations, ensifentrine was recently approved by the FDA as a treatment for patients with chronic obstructive pulmonary disease (COPD). It is anticipated that this novel drug will provide a useful addition to the available treatments for pulmonary diseases.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。